Article Text

Download PDFPDF
EGFR signalling and oncogenic pathway signature in colorectal cancer
  1. Ibrahim Halil Sahin1,
  2. Ahmet Afsin Oktay2
  1. 1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2 Department of Internal Medicine, Saint Francis Hospital, Evanston, Illinois, USA
  1. Correspondence to Dr Ibrahim Halil Sahin, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; ihsahin{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sun et al 1 reported a novel stratification model for classifying patients with colorectal cancer by characterising the gene expression profile of the tumours with wild type and mutant KRAS, BRAF and PIK3CA. The authors claimed that the combined transcription signature of these mutant signal molecules might help clinicians identify patients, whose tumour could have similar transcription signature without any mutation and who …

View Full Text


  • Contributors IHS and AAO were involved in the discussion and manuscript writing process.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.